

On-line Table 1: Patient demographics

Pt	Age (yr)	Sex	Tumor Location	Previous Cycles of IV BV	Steroids	Dose of SIACI BV ^a	Tx after SIACI BV	TTP ^b (Days)	OS ^b (Days)
1	49	M	R frontal	0	Y	14	Lomustine	851	1255
2	60	F	R temporoparietal	0	Y	4	Irinotecan, IV BV	750	889
3	67	F	R parieto-occipital	3.5	Y	6	TMZ, IA cetuximab	1153	1357
4	75	M	R temporal	0	Y	15	RT	435	504
5	51	F	L temporal	0	Y	15	Erlotinib, carboplatin, lomustine	560	–
6	43	M	Brain stem	6	N	8	IA cetuximab	273	336
7	29	F	Posterior body and splenium of corpus callosum, R thalamus	0	Y	15	Irinotecan, IV BV	730	1111
8	52	F	R temporal	0	Y	13	TMZ	340	514
9	61	M	L frontal	0	Y	10	None	185	340
10	66	M	L parietotemporal	9	Y	15	None	–	918
11	61	F	L occipital, L splenium	0	Y	15	Carboplatin	683	956
12	58	F	R parietal	0	Y	15	None	133	252
13	56	M	L insula	0	Y	15	None	350	449
14	55	M	High parasagittal, R parietal	0	Y	15	None	618	848
15	70	M	L temporal	0	Y	15	None	1186	1277
16	81	F	L occipital	0	N	15	None	581	–
17	68	M	L temporal	0	Y	15	None	708	776
18	48	M	R frontal	0	Y	15	None	287	460
19	44	F	L temporal	4	Y	8	Irinotecan, TMZ, IV BV	300	429
20	44	F	R basal ganglia, R frontal, and corpus callosum	0	Y	6	TMZ, IV BV	402	589
21	30	M	L frontal, parietal, and basal ganglia	6	Y	10	None	733	795
22	59	M	R temporoparietal	0.5	Y	15	Operation, IA cetuximab	1062	1152
23	43	M	L temporal	0	Y	15	TMZ, IV BV	231	430
24	53	M	R basal ganglia, genu of corpus callosum	4	Y	6	None	328	384
25	31	F	R parietal, occipital, and splenium of corpus callosum	0	Y	15	Carboplatin	1750	–

Note:—IA indicates intra-arterial; L, left; Pt, patient; R, right; TMZ, temozolomide; Tx, treatment; –, not available; RT, radiotherapy.

^a Dose in milligram/kilogram.

^b TTP and OS were calculated using the date of the operation for primary GBM to the date of radiologic progression of disease after SIACI BV and date of death.

On-line Table 2: Median percentage change in rCBV and rCBF following SIACI

Patient No.	rCBV ^a				rCBF ^a			
	Max Enhancing	Max rCBV	Nonenhancing T2 Hyperintensity	Contralateral NAWM	Max Enhancing	Max rCBV	Nonenhancing T2 Hyperintensity	Contralateral NAWM
1	-66.30	-74.39	-50.59	20.55	-56.93	-63.82	-37.19	-46.12
2	-34.35	-69.71	158.48	-20.00	-43.04	-67.05	-20.67	38.11
3	66.63	-14.11	80.50	22.73	31.44	-25.47	46.15	-11.79
4	-52.79	-13.79	27.75	-32.56	-45.03	-15.25	20.99	67.22
5	16.890	-58.09	136.91	14.75	12.55	-56.74	145.63	-11.15
6	-27.49	-7.41	16.62	2.94	-30.04	-16.82	42.84	-17.12
7	-43.07	-79.18	-42.58	-57.14	-31.80	-76.40	-28.00	51.61
8	-39.46	-39.46	76.22	-4.94	-47.56	-47.56	113.73	29.26
9	-31.86	-47.62	-61.32	143.75	-31.56	-45.45	-44.37	-23.63
10	-20.00	-33.93	5.95	-22.22	-12.29	-30.67	11.16	5.24
11	-33.45	2.38	37.55	10.38	-28.05	13.66	35.38	-20.99
12	117.64	-53.85	96.31	-2.00	55.60	-66.57	63.62	75.74
13	21.69	38.90	184.63	-82.35	15.65	40.36	158.46	-56.60
14	-34.28	-40.98	-13.83	196.55	-37.52	-45.97	-14.74	50.83
15	-28.08	34.83	30.96	-4.26	-30.70	44.18	15.46	0.36
16	-57.80	-36.72	-33.07	-6.76	-54.27	3.25	-21.19	-2.98
17	51.42	-22.99	157.76	4.29	34.75	-23.78	149.41	-10.09
18	-1.16	-29.24	255.42	50.63	-21.11	-40.68	-65.88	68.95
19	1.12	-4.39	23.08	-13.33	21.18	-9.21	23.35	-68.77
20	7.54	21.19	30.04	-17.20	6.00	25.52	21.70	1.59
21	-4.01	-32.24	-6.81	-13.33	0.99	-26.78	-3.42	-0.91
22	-32.84	-12.87	-83.26	0.000	-27.25	-9.19	-73.03	50.63
23	40.87	-38.70	217.37	-6.59	47.83	-45.15	208.97	3.99
24	-25.30	-64.33	-61.21	-26.25	-19.91	-61.04	-63.85	-1.19
25	-31.29	-7.75	145.08	28.57	-66.00	-49.42	61.25	33.46
Median % change (interquartile range)	-34.38-7.55	-47.62 to -7.75	-13.83-136.91	-17.20-14.75	-37.52-12.55	-49.42 to -9.21	-21.19-61.25	-11.79-38.11
P value for median % change ^b	-66.30-117.64	-79.18-38.90	-83.26-255.42	-82.35-196.55	-66.00-55.60	-76.40-44.18	-73.03-208.97	-68.77-75.74
	.074	.001	.069	.568	.037	.001	.216	0696

^a Listed values are calculated as median percentage change = [(Posttreatment - Pretreatment)/Pretreatment × 100%].
^b Listed values are compared with 0% change (null value).

On-line Table 3: Mean percentage change in rCBV and rCBF following SIACI

Pt	rCBV				rCBF			
	Max Enhancing	Max rCBV	Nonenhancing T2 Hyperintensity	Contralateral NAWM	Max Enhancing	Max rCBV	Nonenhancing T2 Hyperintensity	Contralateral NAWM
1	-68.42	-72.42	-51.43	21.48	-54.83	-61.46	-35.23	-45.21
2	-32.39	-71.77	160.57	-21.31	-45.13	-69.13	-22.62	37.05
3	67.54	-13.19	82.49	25.82	29.37	-26.37	45.23	-15.69
4	-53.85	-12.63	25.62	-35.12	-43.12	-14.31	21.87	63.31
5	18.93	-56.17	135.82	15.14	11.42	-58.71	142.72	-10.19
6	-29.53	-6.29	15.54	1.19	-29.17	-14.73	45.75	-18.08
7	-45.13	-79.18	-40.52	-58.23	-33.74	-77.35	-29.11	53.53
8	-37.53	-41.62	78.37	-3.76	-45.48	-46.50	114.59	27.19
9	-33.79	-49.32	-59.43	145.22	-33.43	-43.36	-42.42	-21.71
10	-18.11	-32.83	7.74	-19.75	-10.35	-32.88	9.11	3.17
11	-31.33	3.42	35.49	11.29	-27.13	14.53	33.42	-22.88
12	115.73	-55.83	97.37	-3.20	56.53	-67.61	65.57	73.83
13	23.58	40.85	183.42	-82.35	17.53	41.29	157.43	-55.71
14	-36.42	-40.98	-15.68	194.64	-35.47	-46.89	-13.66	49.91
15	-25.13	35.42	31.93	-2.33	-28.51	45.21	16.53	1.43
16	-60.73	-37.63	-35.13	-6.76	-56.33	2.32	-23.12	-3.89
17	50.51	-23.35	158.62	6.36	35.21	-25.63	150.48	-9.21
18	-0.39	-30.41	256.32	48.57	-22.32	-38.72	-67.79	67.99
19	3.41	-3.43	25.13	-15.47	23.15	-10.37	24.35	-67.63
20	5.71	22.24	31.28	-15.51	4.12	26.49	20.45	0.81
21	-5.17	-35.27	-8.15	-15.21	1.53	-28.63	-5.69	-1.54
22	-31.72	-14.83	-85.63	2.16	-28.19	-7.91	-70.27	51.49
23	39.75	-40.63	219.24	-7.61	45.79	-41.09	210.81	5.81
24	-24.59	-66.38	-62.91	-25.21	-17.32	-65.13	-65.93	-3.71
25	-30.89	-8.09	144.92	27.92	-65.53	-50.09	60.69	34.09